$CNBX
CNBX Pharmaceuticals Inc

2024 Q3 Form 10-Q Financial Statement

#000168316824004831 Filed on July 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $109.4K
YoY Change -50.31%
% of Gross Profit
Research & Development $42.88K
YoY Change -83.7%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $152.3K
YoY Change -68.49%
Operating Profit -$152.3K
YoY Change -12.02%
Interest Expense $21.65K
YoY Change 17.73%
% of Operating Profit
Other Income/Expense, Net $21.65K
YoY Change 17.69%
Pretax Income -$130.6K
YoY Change -15.55%
Income Tax
% Of Pretax Income
Net Earnings -$130.6K
YoY Change -15.55%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 31.11M shares 31.11M shares
Diluted Shares Outstanding 31.11M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.41K
YoY Change 66.27%
Cash & Equivalents $73.41K
Short-Term Investments
Other Short-Term Assets $6.620K
YoY Change -97.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $80.03K
YoY Change -77.06%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $80.03K
Total Long-Term Assets $0.00
Total Assets $80.03K
YoY Change -87.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $189.8K
YoY Change -81.3%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.294M
YoY Change -2.91%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.534M
YoY Change -1.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.534M
Total Long-Term Liabilities $0.00
Total Liabilities $2.534M
YoY Change -1.44%
SHAREHOLDERS EQUITY
Retained Earnings -$24.89M
YoY Change 5.1%
Common Stock $3.111K
YoY Change 94.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.454M
YoY Change
Total Liabilities & Shareholders Equity $80.03K
YoY Change -87.91%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$130.6K
YoY Change -15.55%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities $220.00
YoY Change -101.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $94.67K
YoY Change
Cash From Investing Activities $94.68K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.260K
YoY Change -91.59%
NET CHANGE
Cash From Operating Activities 220.0
Cash From Investing Activities 94.68K
Cash From Financing Activities 1.260K
Net Change In Cash 96.16K
YoY Change -2771.11%
FREE CASH FLOW
Cash From Operating Activities $220.00
Capital Expenditures $0.00
Free Cash Flow $220.00
YoY Change -101.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001343009
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-05-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-52403
dei Entity Registrant Name
EntityRegistrantName
CNBX PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5644005
dei Entity Address Address Line1
EntityAddressAddressLine1
#3 Bethesda Metro Center
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
dei City Area Code
CityAreaCode
(877)
dei Local Phone Number
LocalPhoneNumber
424-2429
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31111352 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73406 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129696 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6621 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
94612 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
80027 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
224308 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
274731 usd
CY2024Q2 us-gaap Assets
Assets
80027 usd
CY2023Q3 us-gaap Assets
Assets
499039 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
189820 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
335915 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1293847 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1343584 usd
CY2024Q2 CNBX Due To Related Party Current
DueToRelatedPartyCurrent
1050731 usd
CY2023Q3 CNBX Due To Related Party Current
DueToRelatedPartyCurrent
836829 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2534398 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2516328 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3111352 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3111352 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22611352 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22611352 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3111 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2261 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22436334 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22239652 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24893816 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24259202 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2454371 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2017289 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80027 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
499039 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
310165 usd
us-gaap Revenues
Revenues
130074 usd
us-gaap Revenues
Revenues
310165 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42884 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
263115 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
268722 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
338330 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
109394 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
220132 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
391958 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
741716 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
152278 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
483247 usd
us-gaap Operating Expenses
OperatingExpenses
660680 usd
us-gaap Operating Expenses
OperatingExpenses
1080046 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-152278 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-173082 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-530606 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-769881 usd
CY2024Q2 CNBX Capital Loss
CapitalLoss
0 usd
CY2023Q2 CNBX Capital Loss
CapitalLoss
0 usd
CNBX Capital Loss
CapitalLoss
-88934 usd
CNBX Capital Loss
CapitalLoss
-2395298 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21646 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18392 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15074 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28499 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-130632 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-154690 usd
us-gaap Net Income Loss
NetIncomeLoss
-634614 usd
us-gaap Net Income Loss
NetIncomeLoss
-3136680 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-59870 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-130632 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-154690 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-634614 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3196550 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31111352 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31111352 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9265865 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9265865 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29964272 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29964272 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4030048 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4030048 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2017289 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104745 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
92787 usd
us-gaap Net Income Loss
NetIncomeLoss
-634614 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2454371 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2358534 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34795 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-130632 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2454371 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1632311 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
470131 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
145505 usd
CNBX Realization Of Available For Sale Asset
RealizationOfAvailableForSaleAsset
2243913 usd
us-gaap Net Income Loss
NetIncomeLoss
-3136680 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1909442 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2011531 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34975 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
221804 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-154690 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1909442 usd
us-gaap Net Income Loss
NetIncomeLoss
-634614 usd
us-gaap Net Income Loss
NetIncomeLoss
-3136680 usd
us-gaap Depreciation
Depreciation
72320 usd
us-gaap Depreciation
Depreciation
123569 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
16798 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
CNBX Capital Loss1
CapitalLoss1
-88934 usd
CNBX Capital Loss1
CapitalLoss1
-2395298 usd
CNBX Convertible Loan Valuation
ConvertibleLoanValuation
0 usd
CNBX Convertible Loan Valuation
ConvertibleLoanValuation
9033 usd
us-gaap Share Based Compensation
ShareBasedCompensation
104745 usd
us-gaap Share Based Compensation
ShareBasedCompensation
145505 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-87991 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
223873 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
67807 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
554110 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-196019 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-133038 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
24702 usd
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
114673 usd
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1196 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113477 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24702 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
26252 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
34972 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
CNBX Costs Of Raising Capital
CostsOfRaisingCapital
0 usd
CNBX Costs Of Raising Capital
CostsOfRaisingCapital
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26252 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34972 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56290 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-73364 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129696 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117515 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73406 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44151 usd
CNBX Exercise Of Convertible Loan To Shares Of Common Stock.
ExerciseOfConvertibleLoanToSharesOfCommonStock.
92787 usd
CNBX Exercise Of Convertible Loan To Shares Of Common Stock.
ExerciseOfConvertibleLoanToSharesOfCommonStock.
470131 usd
us-gaap Net Income Loss
NetIncomeLoss
-634614 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24893816 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
268722 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
338330 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zd3xYUDl60Y3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
us-gaap Share Based Compensation
ShareBasedCompensation
104745 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
8500000 shares
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
92787 usd
CY2024Q1 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
114673 usd
CNBX Capital Loss
CapitalLoss
-88934 usd
CNBX Monthly Operating Lease Expense
MonthlyOperatingLeaseExpense
6500 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-004831-index-headers.html Edgar Link pending
0001683168-24-004831-index.html Edgar Link pending
0001683168-24-004831.txt Edgar Link pending
0001683168-24-004831-xbrl.zip Edgar Link pending
cnbx-20240531.xsd Edgar Link pending
cnbx_ex3101.htm Edgar Link pending
cnbx_ex3102.htm Edgar Link pending
cnbx-20240531_def.xml Edgar Link unprocessable
cnbx_ex3201.htm Edgar Link pending
cnbx_ex3202.htm Edgar Link pending
cnbx_i10q053124.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cnbx_i10q053124_htm.xml Edgar Link completed
cnbx-20240531_lab.xml Edgar Link unprocessable
cnbx-20240531_cal.xml Edgar Link unprocessable
cnbx-20240531_pre.xml Edgar Link unprocessable